A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is checking if talquetamab can help people with multiple myeloma who did not get better after treatment. They will use a certain dose of talquetamab that worked well in previous tests.
This study is checking if talquetamab can help people with multiple myeloma who did not get better after treatment. They will use a certain dose of talquetamab that worked well in previous tests.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
